F

Fluidigm Corp
F:FLB

Watchlist Manager
Fluidigm Corp
F:FLB
Watchlist
Price: 0.795 EUR -1.24% Market Closed
Market Cap: €294.5m

Fluidigm Corp
Short-Term Investments

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Fluidigm Corp
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
F
Fluidigm Corp
F:FLB
Short-Term Investments
$66.7m
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
0%
Thermo Fisher Scientific Inc
NYSE:TMO
Short-Term Investments
$2m
CAGR 3-Years
N/A
CAGR 5-Years
-56%
CAGR 10-Years
-17%
Danaher Corp
NYSE:DHR
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Waters Corp
NYSE:WAT
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Agilent Technologies Inc
NYSE:A
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Short-Term Investments
$161m
CAGR 3-Years
20%
CAGR 5-Years
13%
CAGR 10-Years
5%
No Stocks Found

Fluidigm Corp
Glance View

Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

FLB Intrinsic Value
0.576 EUR
Overvaluation 28%
Intrinsic Value
Price €0.795
F

See Also

What is Fluidigm Corp's Short-Term Investments?
Short-Term Investments
66.7m USD

Based on the financial report for Dec 31, 2025, Fluidigm Corp's Short-Term Investments amounts to 66.7m USD.

What is Fluidigm Corp's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
0%

Over the last year, the Short-Term Investments growth was -47%. The average annual Short-Term Investments growth rates for Fluidigm Corp have been -8% over the past three years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett